Home / Market News / $RZLT

$RZLT news and market catalysts

The 20 most recent market catalysts affecting $RZLT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

20 catalysts 6 high impact 13 bullish 2 bearish Biotechnology
Nov 17, 2026 Corporate Catalyst Bullish Impact 75
Wedbush Raises Price Target on Rezolute to $10 From $6, Keeps Outperform Rating
Wedbush Securities raised its price target for Rezolute (RZLT) from $6 to $10 and reiterated its 'Outperform' rating. This positive adjustment stems from two key developments: succ…
Nov 13, 2026 Corporate Catalyst Neutral Impact 65
Morgan Stanley Acts as Joint Book-Running Manager for Rezolute, Inc. Offering
Rezolute, Inc. is undertaking a public offering to raise $100 million. This capital raise, while providing funds for the company's operations and growth, typically leads to dilutio…
Nov 13, 2026 Corporate Catalyst Neutral Impact 75
Rezolute Prices $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Rezolute, Inc. has announced the pricing of a public offering to raise $100 million through the sale of common stock and pre-funded warrants. This capital is crucial for the compan…
Nov 13, 2026 Corporate Catalyst Bullish Impact 85
Rezolute Announces Positive Results from Phase 3 upLIFT Study in Tumor Hyperinsulinism
Rezolute announced that its Phase 3 upLIFT study for ersodetug in tumor hyperinsulinism met its primary efficacy endpoint, showing a significant reduction in intravenous glucose de…
Nov 5, 2026 Corporate Catalyst Neutral Impact 75
Rezolute, Inc. Reports First Quarter Fiscal 2027 Financial Results
Rezolute, Inc. announced its first-quarter fiscal 2027 financial results, reporting a net loss of $18.5 million, a slight increase from the prior year. While the financial figures …
Oct 30, 2026 Corporate Catalyst Neutral Impact 75
Rezolute Updates Investors on Ersodetug Programs and Financial Position
Rezolute announced a corporate update, highlighting its clinical pipeline and financial status. The company reported $108 million in cash, expected to fund operations through Q1 20…
Oct 6, 2026 Corporate Catalyst Bullish Impact 60
Lake Street Maintains Buy on Rezolute, Raises Price Target to $12
Lake Street analyst Daniel Brims maintained a 'Buy' rating on Rezolute and raised the price target from $9 to $12. This upgrade in the price target suggests that the analyst sees g…
Oct 6, 2026 Corporate Catalyst Bullish Impact 65
Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15
Citizens analyst Jason N. Butler has maintained a 'Market Outperform' rating for Rezolute and raised the price target from $11 to $15. This upgrade in the price target, coupled wit…
Oct 6, 2026 Corporate Catalyst Bullish Impact 65
Cantor Fitzgerald Upgrades Rezolute to Overweight
Cantor Fitzgerald analyst Pete Stavropoulos upgraded Rezolute (RZLT) from Neutral to Overweight. This is a positive development for Rezolute as it indicates a more favorable outloo…
Oct 5, 2026 Corporate Catalyst Bullish Impact 85
Rezolute shares are trading higher after the FDA recommended a pre-BLA meeting with the company following a preliminary review of Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism.
The FDA's recommendation for a pre-BLA meeting following a preliminary review of Phase 3 data is a strong positive signal for Rezolute. This indicates that the FDA likely views the…
Oct 5, 2026 Corporate Catalyst Bullish Impact 85
Rezolute shares are trading higher after the FDA recommended a pre-BLA meeting with the company following a preliminary review of Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism.
This headline is a significant positive catalyst for Rezolute. The FDA's recommendation for a pre-BLA meeting after a preliminary review of Phase 3 data for ersodetug in congenital…
Oct 5, 2026 Corporate Catalyst Bullish Impact 92
Rezolute shares are trading higher after the company announced that the FDA recommended a pre-BLA meeting following a preliminary review of data from its Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital hyperinsulinism.
This headline represents a major positive catalyst for Rezolute. The FDA's recommendation for a pre-BLA (Biologics License Application) meeting indicates that the preliminary revie…
Oct 5, 2026 Corporate Catalyst Bullish Impact 65
FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints
Rezolute's drug, ersodetug, for congenital hyperinsulinism, initially failed its Phase 3 trial by missing primary and key secondary endpoints based on finger-stick measurements. Ho…
Oct 5, 2026 Corporate Catalyst Bullish Impact 75
Rezolute Gets FDA Recommendation For Pre-BLA Meeting Ahead Of Ersodetug BLA Submission For Congenital Hyperinsulinism Treatment.
Rezolute received a significant positive signal from the FDA, which recommended a pre-BLA meeting for its drug ersodetug for congenital hyperinsulinism. This is notable because the…
Sep 30, 2026 Corporate Catalyst Neutral Impact 55
Lake Street Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $9
Lake Street analyst Daniel Brims initiated coverage on Rezolute (RZLT) with a 'Buy' rating and a $9 price target. This event is significant for RZLT as it introduces new institutio…
Sep 29, 2026 Corporate Catalyst Bullish Impact 65
Craig-Hallum Upgrades Rezolute to Buy, Raises Price Target to $7
Craig-Hallum analyst Albert Lowe upgraded Rezolute (RZLT) from Hold to Buy and raised the price target from $4 to $7. This analyst action is a positive signal for investors, indica…
Sep 25, 2026 Corporate Catalyst Bullish Impact 65
HC Wainwright & Co. Maintains Buy on Rezolute, Raises Price Target to $10
HC Wainwright & Co. analyst Douglas Tsao has maintained a 'Buy' rating on Rezolute (RZLT) and doubled the price target from $5 to $10. This significant upgrade indicates a strong b…
Sep 24, 2026 Corporate Catalyst Bearish Impact 92
Rezolute Q4 EPS $(0.20) Misses $(0.15) Estimate
Rezolute announced its Q4 earnings, reporting a loss of $(0.20) per share, which was 33.33% worse than the analyst consensus estimate of $(0.15). This significant miss indicates th…
Sep 9, 2026 Corporate Catalyst Bearish Impact 85
Rezolute shares are trading lower after the company announced that data from the Phase 3 sunRIZE study still remains under review by the FDA.
This headline is a significant corporate catalyst for Rezolute (RZLT) as it directly impacts the company's primary drug candidate. The continued FDA review, rather than an approval…
Sep 9, 2026 Corporate Catalyst Bullish Impact 65
Rezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company Continues To Await Feedback And Reserves The Ability To Request Formal Meeting Under Regulatory Timeline
Rezolute's 8-K filing indicates that the FDA is still reviewing the Ersodetug submission for congenital hyperinsulinism, and the company is awaiting feedback. This update suggests …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.